home / stock / clrb / clrb news


CLRB News and Press, Cellectar Biosciences Inc. From 03/19/24

Stock Information

Company Name: Cellectar Biosciences Inc.
Stock Symbol: CLRB
Market: NASDAQ
Website: cellectar.com

Menu

CLRB CLRB Quote CLRB Short CLRB News CLRB Articles CLRB Message Board
Get CLRB Alerts

News, Short Squeeze, Breakout and More Instantly...

CLRB - AstraZeneca-Fusion deal reignites radiopharma space

2024-03-19 08:19:47 ET More on Fusion Pharmaceuticals Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook Biggest stock movers today: FUSN, NCMI, crypto stocks and more AstraZeneca will buy Fusion Pharmaceuticals for ~$2B Seeking Alpha’s ...

CLRB - Cellectar Biosciences to Present at the 36th Annual Roth Conference

FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that Jim Caruso, president and chie...

CLRB - Expected US Company Earnings on Thursday, March 14th, 2024

AIA Group Limited ADR (AAGIY) is expected to report for Q4 2023 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 SecureWorks Corp. (SCWX) is expected to report $-0.15 for Q4 2024 Acacia Research Corporation (ACTG) is expected to report for quarter end...

CLRB - Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

Complete Remission rate of 64% and Overall Response Rate of 73% demonstrated in highly refractory patients Durability of clinical activity achieved 67% Overall Survival and 42% Progression Free Survival at One Year FLORHAM PARK, N.J., March 04, 2024 (GLOBE NEWSWIRE) --  ...

CLRB - Radiopharmaceutical market expected to reach ~$14B by 2032

2024-02-25 12:00:00 ET More on AstraZeneca, Bristol-Myers, etc. Eli Lilly: Will It Be The First Ever Trillion-Dollar Drug Company? Eli Lilly: Yes, It Is Too Late To Join The Party Eli Lilly: Very Strong Fundamentals, But Market Is Euphoric Phase 3 data for As...

CLRB - Cellectar Biosciences: A Shoestring Opportunity You're About To Miss

2024-02-12 01:34:26 ET Summary Cellectar Biosciences is a developmental biotech focused on a radiolabeled phospholipid for hematologic malignancies, with a focus on Waldenstrom's macroglobulinemia. Their most advanced development is in Waldenstrom's, with positive trial results an...

CLRB - Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

FLORHAM PARK, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president and chi...

CLRB - Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study

FLORHAM PARK, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the first patient has been enrolled i...

CLRB - Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million

FLORHAM PARK, N.J., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Tranche A warrants issued as...

CLRB - Cellectar stock climbs 8% on results for CNS malignancy therapy

2024-01-22 12:47:02 ET More on Cellectar Biosciences Cellectar Biosciences, Inc. (CLRB) Q3 2023 Earnings Call Transcript Cellectar Biosciences gains on pivotal data for radiotherapy Seeking Alpha’s Quant Rating on Cellectar Biosciences Historical earni...

Previous 10 Next 10